D. E. Shaw & Co., Inc. Charles River Laboratories International, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 607,019 shares of CRL stock, worth $99.1 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

607,019

Previous 1,600 37838.69%

Holding current value

$99.1 Million

Previous $240,000 38275.83%

% of portfolio

0.07%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$99.75 - $151.89 $60.6 Million - $92.2 Million	607,019 New	607,019 $92.1 Million
Q4 2024 Feb 14, 2025	BUY	$178.58 - $220.69 $15.1 Million - $18.7 Million	84,656 New	84,656 $15.6 Million
Q4 2023 Feb 14, 2024	BUY	$164.52 - $238.84 $614,811 - $892,545	3,737 Added 333.66%	4,857 $1.15 Million
Q3 2023 Nov 14, 2023	BUY	$194.44 - $217.61 $217,772 - $243,723	1,120 New	1,120 $219,000
Q1 2023 May 15, 2023	SELL	$191.89 - $259.92 $4.35 Million - $5.9 Million	-22,687 Reduced 65.36%	12,022 $2.43 Million
Q4 2022 Feb 14, 2023	SELL	$197.11 - $250.07 $13.1 Million - $16.6 Million	-66,323 Reduced 65.65%	34,709 $7.56 Million
Q3 2022 Nov 14, 2022	SELL	$182.44 - $250.54 $12.1 Million - $16.6 Million	-66,438 Reduced 39.67%	101,032 $19.9 Million
Q2 2022 Aug 15, 2022	BUY	$204.13 - $302.4 $12.1 Million - $17.9 Million	59,310 Added 54.84%	167,470 $35.8 Million
Q1 2022 May 16, 2022	BUY	$255.51 - $362.11 $27.4 Million - $38.8 Million	107,148 Added 10587.75%	108,160 $30.7 Million
Q4 2021 Feb 14, 2022	SELL	$351.38 - $448.68 $637,754 - $814,354	-1,815 Reduced 64.2%	1,012 $381,000
Q3 2021 Nov 15, 2021	BUY	$372.64 - $458.3 $739,690 - $909,725	1,985 Added 235.75%	2,827 $1.17 Million
Q2 2021 Aug 16, 2021	BUY	$294.17 - $371.65 $247,691 - $312,929	842 New	842 $311,000
Q1 2021 May 17, 2021	SELL	$249.67 - $299.48 $3.82 Million - $4.58 Million	-15,306 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$222.0 - $252.62 $1.62 Million - $1.85 Million	-7,309 Reduced 32.32%	15,306 $3.82 Million
Q3 2020 Nov 16, 2020	SELL	$175.56 - $226.45 $2.27 Million - $2.93 Million	-12,936 Reduced 36.39%	22,615 $5.12 Million
Q2 2020 Aug 14, 2020	SELL	$118.84 - $189.72 $2.46 Million - $3.93 Million	-20,693 Reduced 36.79%	35,551 $6.2 Million
Q1 2020 May 15, 2020	BUY	$98.9 - $178.34 $1.38 Million - $2.48 Million	13,934 Added 32.93%	56,244 $7.1 Million
Q4 2019 Feb 14, 2020	SELL	$126.05 - $152.76 $6.28 Million - $7.61 Million	-49,817 Reduced 54.07%	42,310 $6.46 Million
Q3 2019 Nov 14, 2019	BUY	$125.07 - $143.67 $3.43 Million - $3.94 Million	27,430 Added 42.4%	92,127 $12.2 Million
Q2 2019 Aug 14, 2019	SELL	$123.4 - $148.55 $6.47 Million - $7.78 Million	-52,401 Reduced 44.75%	64,697 $9.18 Million
Q1 2019 May 15, 2019	BUY	$104.82 - $146.73 $1.68 Million - $2.35 Million	16,011 Added 15.84%	117,098 $17 Million
Q4 2018 Feb 14, 2019	SELL	$105.09 - $137.23 $12.5 Million - $16.4 Million	-119,307 Reduced 54.13%	101,087 $11.4 Million
Q3 2018 Nov 14, 2018	BUY	$112.11 - $134.54 $7.1 Million - $8.52 Million	63,322 Added 40.31%	220,394 $29.7 Million
Q2 2018 Aug 14, 2018	BUY	$102.37 - $117.25 $2.58 Million - $2.95 Million	25,154 Added 19.07%	157,072 $17.6 Million
Q1 2018 May 15, 2018	SELL	$98.19 - $115.2 $28.3 Million - $33.2 Million	-288,049 Reduced 68.59%	131,918 $14.1 Million
Q4 2017 Feb 14, 2018	SELL	$100.43 - $118.09 $22.3 Million - $26.2 Million	-221,707 Reduced 34.55%	419,967 $46 Million
Q3 2017 Nov 14, 2017	BUY	$96.72 - $109.26 $62.1 Million - $70.1 Million	641,674	641,674 $69.3 Million

Others Institutions Holding CRL

# of Institutions

615

Shares Held

53.2M

Call Options Held

1.42M

Put Options Held

1.42M

View Full List

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $8.31B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

More about CRL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account